WASHINGTON — President Joe Biden is set to meet with infant formula manufacturers as his administration works to ease nationwide shortages by importing foreign supplies and using the Defense Production Act to speed domestic production.
The White House said a third round of formula shipments from overseas will begin next week, this time from producer Kendamil in Britain. Shipments from Bubs Australia will be delivered next week as well.
The White House said Biden would host a roundtable Wednesday with leaders of manufacturers ByHeart, Bubs Australia, Reckitt, Perrigo Co. and Gerber. The list is notable for the absence of Abbott Nutrition, whose Michigan plant was shut down in February over safety concerns, sparking the shortage in the United States.
Biden will be joined by Heath and Human Services Secretary Xavier Becerra and Surgeon General Vivek Murthy. The meeting is expected to provide an update on what the administration is calling “Operation Fly Formula” to import formula and to use the Korean War-era production law to require suppliers of the formula manufacturers to prioritize their orders in a bid to ease any production bottlenecks.
The White House said the latest round of shipments would bring Kendamil formula from Heathrow Airport in London to U.S. airports over a three-week period, starting June. 9. The flights will carry about 3.7 million 8-ounce bottle equivalents, shipped free of charge by United Airlines.
The first shipments will include Kendamil Classic Stage 1 and Kendamil Organic formulas, which will be available at Target stores across the United States.
Bubs Australia will ship the equivalent of 4.6 million 8-ounce bottles of its infant formula on Defense Department-contracted commercial aircraft from its hub in Melbourne, Australia, to Pennsylvania and California on June 9 and June 11, respectively.
The push on imports will help but will not immediately bring an end to supply shortages that have left people who depend on formula facing empty shelves or limits on purchases.
The Food and Drug Administration began focusing on Abbott’s plant last fall while tracking several bacterial infections in infants who had consumed formula from the facility. The four cases occurred between September and January, causing hospitalizations and two deaths.
After detecting positive samples of rare but dangerous bacteria in multiple parts of the plant, the FDA closed the facility and Abbott announced a massive recall of its formula on Feb. 17.
U.S. regulators and Abbott announced an agreement last month that would help pave the way for reopening the plant, though production has not restarted.
The White House did not respond to a request for comment on why Abbott was not included from Wednesday’s meeting.
By Zeke Miller, Associated Press
